A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

The choice should be at the discretion of physicians based on the availability and cost of the two drugs in different regions ... other ERCP-related complications (eg, gastrointestinal bleeding, ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8540 ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

This and the forthcoming drug are part of Sunshine Biopharma’s strategy to penetrate the chronic idiopathic constipation market, which is part of the larger gastrointestinal market with annual sales ...

Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently ...

This and the forthcoming drug are part of Sunshine Biopharma’s strategy to penetrate the chronic idiopathic constipation market, which is part of the larger gastrointestinal market with annual ...